Lipid-lowering medications, such as statins (coenzyme A reductase inhibitors), fibrates, and PCSK9 inhibitors, are first-line in the management of hyperlipidemia and aim to reduce serum circulating lipids thereby reducing the risk of cardiovascular events such as myocardial infarction (MI), stroke, and significant lower extremity amputations resulting from peripheral arterial occlusive disease29–31. The gene discussed is PCSK9; the disease is myocardial infarction.